Immatics N.V.
IMTX
$9.91
-$0.24-2.37%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
1/24/2026
-
Tickeron - Technical Analysis
1/23/2026
-
Tickeron - Stocks
1/21/2026
-
Tickeron - Stocks
1/21/2026
-
Tickeron - Stocks
1/12/2026
-
Ticker Report
1/11/2026
-
MarketBeat
1/9/2026
-
Tickeron - Stocks
1/8/2026
-
MarketBeat
1/7/2026
-
Tickeron - Stocks
1/6/2026
-
TipRanks Financial Blog
1/6/2026
-
The Fly
1/6/2026
-
Tickeron - Technical Analysis
1/6/2026
-
Tickeron - Technical Analysis
1/5/2026
-
MarketBeat
1/5/2026
-
Ticker Report
1/3/2026
-
MarketBeat
1/1/2026
-
Tickeron - Stocks
1/1/2026
-
Tickeron - Stocks
12/31/2025
-
MarketBeat
12/31/2025
-
Tickeron - Stocks
12/25/2025
-
SeekingAlpha
12/25/2025
-
Seeking Alpha - Long Ideas
12/25/2025
-
SeekingAlpha.com: Most Popular Articles
12/18/2025
-
Tickeron - Stocks
12/17/2025
-
Tickeron - Stocks
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
--
Net Income (TTM)
--
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
--
Cash from Investing (TTM)
--
Cash from Financing (TTM)
--
Net Change in Cash (TTM)
--
Filings
Filing Date
Monday, November 17, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Mar 23 and 27 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
49 7071 5397 0
Address
Paul-Ehrlich-Strasse 15
Tübingen, 72076
Tübingen, 72076
Country
Year Founded
--
Business Description
Sector
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United...
more